Allergan
In Mason Hawkins's portfolio · Longleaf Partners
Ticker AGN
Not in the portfolio as of Q3 2026. Every quarter it shows up in a Longleaf Partners 13F, newest first.
| Quarter | Activity | Shares | Weight |
|---|---|---|---|
| Q3 2019 | Sell | 0 | |
| Q2 2019 | Reduce 36% | 1,288,500 | 3.5% |
| Q1 2019 | Reduce 6% | 2,027,545 | 4.3% |
| Q4 2018 | Reduce 6% | 2,147,382 | 4.1% |
| Q3 2018 | Reduce 23% | 2,295,059 | 5.2% |
| Q2 2018 | Reduce 4% | 2,989,405 | 5.6% |
| Q1 2018 | Add 36% | 3,119,124 | 6.4% |
| Q4 2017 | Buy | 2,297,386 | 4.7% |
Price is the position's value divided by its shares, at the end of each quarter. Share counts are as filed; when a stock split happened, the change is measured on split-adjusted shares.